Symptom tracking + personalized care for Endo/PCOS sufferers

About 200 million women worldwide experience endometriosis or PCOS, conditions characterized by chronic pain, irregular cycles, infertility risk and substantial quality-of-life impact, with many patients facing multi-year diagnostic delays and fragmented care. These patients and their clinicians lack standardized, longitudinal symptom data that reliably links individual patterns to treatment responses, which makes iterative care inefficient and often reactive rather than personalized. You could build a HIPAA‑grade symptom-tracking platform that combines daily structured logs, wearable and cycle-data integration, clinician dashboards, and ML models that surface individualized symptom triggers and response-to-treatment signals from longitudinal data, plus telehealth workflows and validated PROs for clinical use. The market looks attractive now: a conservative addressable market of $7.2B (200M users × $36 ARPU/year), a Market Score of 85/100 and Revenue Potential 80/100, driven by telehealth normalization, rapid advances in AI personalization, and destigmatization that increase user adoption and clinician acceptance. This opportunity is realistic but not trivial; competitive intensity is medium and success will hinge on sustained user engagement, clinical validation (ideally RCT or real-world outcomes), strong privacy/regulatory posture, and care-provider partnerships. Differentiation should come from clinically validated personalization, seamless telehealth/EMR interoperability, and clear B2B routes (specialist clinics, payors) to complement consumer subscriptions; the strengths are a large recurring-revenue market and demonstrable clinical value, while the primary challenges are adherence, evidence generation, and navigating reimbursement and liability.